Loading...
Market
Story
Merck and Moderna Launch Phase 3 Trial for V940 and KEYTRUDA in Lung Cancer Treatment
Oct 28, 2024, 10:47 AM
Merck and Moderna have initiated a Phase 3 trial to evaluate the efficacy of their investigational individualized neoantigen therapy, V940 (mRNA-4157), in combination with KEYTRUDA (pembrolizumab) and immunotherapy for patients with certain types of non-small cell lung cancer (NSCLC). This trial follows the use of neoadjuvant KEYTRUDA and chemotherapy. The adjuvant mRNA vaccine, a cousin to the COVID-19 vaccines, has entered human trials as a treatment for lung cancer. This marks the third Phase 3 trial for the V940 cancer vaccine and the second specifically targeting early-stage lung cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50 months • 25%
50-60 months • 25%
60-70 months • 25%
More than 70 months • 25%
Exceeds regulatory criteria • 25%
Meets regulatory criteria • 25%
Fails to meet regulatory criteria • 25%
Trial delayed or inconclusive • 25%
Yes • 50%
No • 50%